Loading clinical trials...

A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease | Clinical Trials | Clareo Health

COMPLETEDPhase 3

A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease

A Phase 3, Multicenter, Randomized, Doubleblind, Placebo-controlled, Parallel Group Study, Followed by an Active-treatment Phase to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Subjects With Active Behcet's Disease

NCT02307513•Amgen

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Behçet's Syndrome

Interventions

Apremilast

Placebo

Locations

63

United States

Locations (63)

Arizona Arthritis and Rheumatology Research, PLLC

Phoenix, Arizona, United States

University of California Davis Medical Center

Sacramento, California, United States

Millennium Research

Ormond Beach, Florida, United States

Arthritis and Rheumatology of Georgia

Atlanta, Georgia, United States

Northwestern University Feinberg School of Medicine

Chicago, Illinois, United States

Advanced Rheumatology

Lansing, Michigan, United States

Key Dates

Start Date

December 30, 2014

Primary Completion Date

September 25, 2017

Completion Date

July 17, 2020

Last Updated

July 22, 2021

Related Studies

Ustekinumab in BEhçet's Syndrome STudy

NCT07244614

Behçet's Syndrome (BS)

RECRUITINGPhase 1

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

NCT06371417

Antiphospholipid Syndrome (APS)Bullous Pemphigoid (BP)+4 more

Withdrawal of Colchicine in Behçet Syndrome

NCT06146192

Behçet's Syndrome

Sponsors

Lead Sponsor

Amgen

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 22, 2021Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions